Region Skane Angelholms Sjukhus
- Address
- lock Available on a paid plan
Infection Management & Wound Healing
The Region Skane Angelholms Sjukhus is advancing care for patients with diabetic foot ulcer by testing novel topical antimicrobials to shorten healing time and reduce infection complications.
- Evaluation of local antimicrobial agents
- Assessment of time‑to‑healing outcomes
- Implementation of randomized double‑blind methodology
- Integration of advanced wound‑care protocols
This research aims to identify more effective treatments that can be adopted in routine practice, improving recovery rates for individuals affected by bacterial infections of the foot.
Bladder Cancer Adjuvant Therapy
In the Urologmottagningen, investigators are comparing adjuvant gemcitabine with mitomycin to enhance recurrence‑free survival for patients with non‑muscle invasive bladder cancer at intermediate risk.
- Adjuvant intravesical chemotherapy strategies
- Risk‑adjusted patient selection
- Focus on recurrence‑free survival metrics
- Collaboration across oncology and urology specialties
The study seeks to refine therapeutic options that could lower tumor recurrence rates and inform future clinical guidelines for bladder cancer management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1University Of Gothenburg1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Skane Angelholms Sjukhus
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Study of Adjuvant Gemcitabine Versus Mitomycin in Intermediate-Risk Non-Muscle Invasive Bladder Cancer | Region Skane | Phase III | Not Recruiting | Mar 2021 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Gemcitabine | 1 | Unknown | 2021-03-16 | 2021-03-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.